Prevention of vancomycin induced nephrotoxicity: A review of preclinical data

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 747-754

  Elyasi, Sepideh ^a   Khalili, Hossein ^a   Hatamkhani, Shima ^a   Dashti Khavidaki, Simin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nephrotoxicity; Prevention; Vancomycin

Indexed keywords

1,5 ISOQUINOLINEDIOL; 2,3 DIHYDROXYBENZOIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMRINONE; ASCORBIC ACID; ATORVASTATIN; CAFFEIC ACID PHENETHYL ESTER; CILASTATIN; CILASTATIN PLUS IMIPENEM; CURCUMIN; ERDOSTEINE; ERYTHROPOIETIN; FOSFOMYCIN; GENTAMICIN; GINKGO BILOBA EXTRACT; HEXAMETHYLENE DIAMINE CONJUGATED SUPEROXIDE DISMUTASE; MELATONIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SUPEROXIDE DISMUTASE; TEICOPLANIN; TEMPOL; THIOCTIC ACID; THYMOQUINONE; UNCLASSIFIED DRUG; VANCOMYCIN;

CLINICAL PRACTICE; COCHRANE LIBRARY; DRUG INDUCED DISEASE; INFORMATION PROCESSING; INFORMATION RETRIEVAL; KIDNEY FAILURE; KIDNEY INJURY; MEDLINE; NEPHROTOXICITY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL PROTECTION; RETROSPECTIVE STUDY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; KIDNEY DISEASES; TISSUE DISTRIBUTION; VANCOMYCIN;

EID: 84876726800     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1406-3     Document Type: Review

References (56)

1. Hodoshima N, Masuda S, Inui K (2007) Decreased renal accumulation and toxicity of a new VCM formulation in rats with chronic renal failure. Drug Metab Pharmacokinet 22:419-427
2. Bailie GR, Neal D (1998) Vancomycin ototoxicity and nephrotoxicity, a review. Med Toxicol 3:376-386
3. Lodise TP, PatelN LBM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity. Clini Infect Dis 49:507-514
4. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52(4):1330-1336
5. Elting LS, Rubenstein EB, Kurtin D (1998) Mississippi mud in the 1990s: Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83(12):2597-2607
6. Newton P (2004) The role of monitoring serum vancomycin concentrations. Phatol 2(2):1-2
7. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Da F (2008) Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. Antimicrob Agents Chemother 62:168-171
8. Moellering RC (2006) Vancomycin: A 50-year reassessment. Clin Infect Dis 1S:3-4
9. Levine DP (2006) Vancomycin: A history. Clin Infect Dis 42[S1]:5-12
10. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68(9):1243-1255
11. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38(12):1673-1681
12. Wilcox MH, Tack KJ, Bouza E (2009) Complicated skin and skin-structure infections and catheter related bloodstream infections: Noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48(2):203-212
13. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A (2011) Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 55(7):3278-3283
14. Toyoguchi T, Takahashi S, Hosoya J, Nakagawa Y, Watanabe H (1997) Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 41:1985-1990
15. Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Ogino T, Inoue M, Okada S, Kinoshita H (2003) Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res 37(4):272-279
16. Oktema F, Arslan FK, Ozguner F, Candir O, Yilmaz HR, Ciris M, Uz E (2005) In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: Protection by erdosteine. Toxicology 215:227-233
17. King DW, Smith MA (2004) Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicology 18:797-803
18. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH (2005) Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 97:325-332
19. Cetin H, Olgar S, Oktem F (2007) Novel evidence suggesting an antioxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 34:1181-1185
20. Hodoshima N, Nakano Y, Izumi M (2004) Protective effect of inactive ingredients against nephrotoxicity of vancomycin hydrochloride in rats. Drugs Metab Pharmacokinet 19(1):68-75
21. Ladino M, Alex M, Schulman IH (2008) Acute and reversible vancomycin nephrotoxicity: A case series. J Nephrol Ren Transplant 3:4-10
22. Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Tanaka H, Inoue M, Okada S, Kinoshita H (2002) Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat. Redox Rep 7(5):317-319
23. Abraham NG, Asija A, Drummond G, Peterson S (2007) Heme oxygenase-1 gene therapy: Recent advances and therapeutic applications. CurrGene Ther 7(2):89-108
24. Scandalios JG (2005) Oxidative stress: Molecular perception and transduction of signals triggering antioxidant gene defenses. Brazi J Med Biol Res 38(7):995-1014
25. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG (2010) Vancomycin-associated nephrotoxicity: Grave concern or death by character assassination? Am J Med 123(2):182-193
26. Dieterich C, Puey A, Lyn S, Swezey R, Furimsky A, Fairchild D, Mirsalis JC, Ng HH (2009) Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci 107(1):258-269
27. Fanos V, Cataldi L (2001) Renal transport of antibiotics and nephrotoxicity: A review. J Chemother 13(5):461-472
28. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant staphylococcus aureus infections. Arch Intern Med 166:2138-2144
29. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME (2010) Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 9:9-14
30. Dechant KL, Noble S (1996) Erdosteine. Drugs 52:875-881
31. Young IS, Woodside IS (2001) Antioxidants in health and disease. J Clin Pathol 54:176-186
32. Kumar KV, Naidu MU, Shifow AA, Prayag A, Ratnakar KS (1999) Melatonin: An antioxidant protects against cyclosporine-induced nephrotoxicity. Transplantation 67:1065-1068
33. Fukaya H, Kanno H (1999) Experimental studies of the protective effect of ginkgo biloba extract (Ginko biloba extract) on cisplatin- induced toxicity in rats. Nippon Jibiinkoka Gakkai Kaiho 102:907-917
34. Carlini RG, Reyes AA, Rothstein M (1995) Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745
35. Westenfelder C, Biddle DL, Baranowski RL (1999) Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55:808-820
36. Sharples EJ, Patel N, Brown P et al (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115-2124
37. Badary OA, Nagi MN, al-Shabanah OA, al-Sawaf HA, al-Sohaibani MO, al-Bekairi AM (1997) Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 75(12):1356-1361
38. Basarslan F, Yilmaz N, Ates S, Ozgur T, Tutanc M, Motor VK, Arica V, Yilmaz C, Inci M, Buyukbas S (2012) Protective effects of thymoquinone on vancomycin-induced nephrotoxicity in rats. Hum Exp Toxicol 31(7):726-733
39. Parlakpinar H, Tasdemir S, Polat A et al (2005) Protective role of caffeic acid phenethyl ester (CAPE) on gentamicin-induced acute renal toxicity in rats. Toxicology 207:169-177
40. Loong CC, Chang YH, Wu TH et al (2004) Antioxidant supplementation may improve renal transplant function: A preliminary report. Transplant Proc 36:2438-2439
41. Kadkhodaee M, Khastar H, Faghihi M, Ghaznavi R, Zahmatkesh M (2005) Effects of co-supplementation of vitamins E and C on gentamicin-induced nephrotoxicity in rat. Exp Physiol 90:571-576
42. Mazzon E, Britti D, De Sarro A, Caputi AP, Cuzzocrea S (2001) Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 424:75-83
43. Ocak S, Gorur S, Hakverdi S, Celik S, Erdogen S (2007) Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 100:328-333
44. Naik RS, Mujumdar AM, Ghaskadbi S (2004) Protection of liver cells from ethanol cytotoxicity by curcumin in liver slice culture in vitro. J Ethnopharmacol 95:31-37
45. Ahmida MH (2012) Protective role of curcumin in nephrotoxic oxidative damage induced by vancomycin in rats. Exp Toxicol Pathol 64(3):149-153
46. Wilcox CS (2010) Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther 126 (2):119-145
47. Graziano JH, Grady RW, Cerami A (1974) The identification of 2,3-dihroxybenzoic acid as a potentially useful iron-chelating drug. J Pharmacol Exp Ther 190(3):570-575
48. Naghibi B, Ghafghazi T, Hajhashemi V, Talebi A (2007) The effect of 2,3-dihydroxybenzoic acid and tempol in prevention of vancomycin-induced nephrotoxicity in rats. Toxicology 232(3):192-199
49. Haendeler J, Hoffmann J, Zeiher AM, Stefanie D (2004) Antioxidant effects of statins via s-nitrosylation and activation of thioredoxin in endothelial cells a novel vasculoprotective function of statins. Circulation 110:856-861
50. Panonnummal R, Varkey J, Dinoop DR (2011) Protective effect of atorvastatin against vancomycin induced nephrotoxicity in albino rats. Pharmacie Globale 2(8):1-6
51. Zhang J, Dawson VL, Dawson TM Snyder SH (1994) Nitric oxide activation of poly (ADP-ribose) synthetase in neurotoxicity. Science 263(5147):687-689
52. Dalaklioglu S, Tekcan M, Gungor NE, Celik-Ozenci C, Aksoy NH, Baykal A, Tasatargil A (2010) Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury. Toxicol Lett 192:91-96
53. Nishikawa M, Nagatomi H, Chang BJ, Sato E, Inoue M (2001) Targeting superoxide dismutase to renal proximal tubule cells inhibits mitochondrial injury and renal dysfunction induced by cisplatin. Arch Biochem Biophys 387:78-84
54. Toyoguchi T, Nakagawa Y (1996) Nephrotoxicity and drug interaction of vancomycin. Nippon Yakurigaku Zasshi 107(5):225-235
55. Nakamura T, Hashimoto Y, Kohuryo T, Inui K (1998) Effects of fosfomycin and imipenem-cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceut Res 15(5):734-738
56. Yoshiyama Y, Yazaki T, Wong PC, Beauchamp D, Kanke M (2001) The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats. J Infect Chemother 7(4):243-246